Search results
Results from the WOW.Com Content Network
Additionally, Tedizolid was shown to have fewer treatment-related side effects than linezolid and significantly fewer GI side effects. [ 6 ] Trius was planning the second Phase 2 trial and expects to report results around the end of Q1 2013 and planned to submit an NDA to the FDA for the drug in the second half of 2013.
Tedizolid phosphate is a phosphate ester prodrug of the active compound tedizolid. It was developed by Cubist Pharmaceuticals , following acquisition of Trius Therapeutics (originator: Dong-A Pharmaceuticals), and is marketed for the treatment of acute bacterial skin and skin structure infections (also known as complicated skin and skin ...
Linezolid is a member of the oxazolidinone class of medications. [10] Linezolid was discovered in the mid-1990s, and was approved for commercial use in 2000. [16] [17] It is on the World Health Organization's List of Essential Medicines. [18] The World Health Organization classifies linezolid as critically important for human medicine. [19]
Antibiotics that usually have activity against vancomycin-resistant Enterococcus (VRE): . Linezolid and Tedizolid; Streptogramins such as quinupristin-dalfopristin; Advanced generation tetracyclines: Tigecycline, Omadacycline, Eravacycline
It differs from linezolid by replacement of the morpholine oxygen with a sulfur atom. Like linezolid, sutezolid is a bacterial protein synthesis inhibitor . In preclinical studies, sutezolid demonstrated superior antituberculosis activity compared to linezolid.
Lincosamides consist of a pyrrolidine ring linked to a pyranose moiety (methylthio-lincosamide) via an amide bond. [2] [3] Hydrolysis of lincosamides, specifically lincomycin, splits the molecule into its building blocks of the sugar and proline moieties.
The WHO Model List of Essential Medicines (aka Essential Medicines List or EML [1]), published by the World Health Organization (WHO), contains the medications considered to be most effective and safe to meet the most important needs in a health system. [2]
Staphylococcus haemolyticus is a member of the coagulase-negative staphylococci (CoNS). [2] It is part of the skin flora of humans, [3] and its largest populations are usually found at the axillae, perineum, and inguinal areas. [4]